Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$11.11 USD
-0.39 (-3.39%)
Updated May 31, 2024 04:00 PM ET
After-Market: $11.10 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 1 - 20 ( 160 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zurzuvae Offers Reason For Optimism, Though More Cautious View on Dalzanemdor Lowers Price Target to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zurzuvae Off To A Nice Start; Additional SAGE-718 Readouts To Come
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SAGE-718 Misses the Mark in Parkinson''s Disease; Reit. Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Not Setting A PRECEDENT With SAGE-718 Parkinson''s HD, AD Still To Come
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Positive Signals for Zurzuvae in Its Early Days; Price Target Raised to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zurzuvae Launch Underway, As We Look Ahead To SAGE-718 Readouts In HD
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Quick Thoughts Ahead of 4Q, Target to $25 on PPD-Only Thesis for Zurzuvae; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
NNARR Below Buyside Expects; ARR Guided Down; Is FY25E Guide at Risk?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department